Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer

Hung-Jui Tan, MD
Edward C. Norton, PhD
Zaojun Ye, MS
Khaled S. Hafez, MD
John L. Gore, MD, MS
David C. Miller, MD, MPH

THE INCIDENCE OF KIDNEY CANCER has risen inexorably over the last 2 decades due mainly to an increasing number of patients diagnosed with small renal tumors (≤4 cm). Although radical nephrectomy had long been the standard treatment for these patients, partial nephrectomy (ie, surgical removal of the tumor only) is now the preferred treatment option based on its provision of equivalent cancer control and better preservation of long-term renal function. Several observational studies have also demonstrated better survival following partial vs radical nephrectomy, a finding that is generally attributed to the avoidance of chronic kidney disease–related morbidity and mortality.

More recently, however, long-term data from a multicenter, randomized trial comparing outcomes among patients treated for small kidney cancers identified a survival benefit for those treated with radical (vs partial) nephrectomy. Nonetheless, this study, conducted by the European Organization for Research and Treatment of Cancer (EORTC), had several notable limitations (eg, accrual difficulties, premature closure) and occurred in an era when most surgeons rarely performed partial nephrectomy. As such, many argue that the EORTC trial is not generalizable to contemporary practice.

Because the likelihood of better designed trials is low, we performed an instrumental variable analysis using linked Surveillance, Epidemiology and End Results (SEER) and Medicare data to compare long-term survival among patients treated with partial vs radical nephrectomy. Instrumental variable analysis is an econometric method that leverages an econometric method that leverages

Context Although partial nephrectomy is the preferred treatment for many patients with early-stage kidney cancer, recent clinical trial data, which demonstrate better survival for patients treated with radical nephrectomy, have generated new uncertainty regarding the comparative effectiveness of these treatment options.

Objective To compare long-term survival after partial vs radical nephrectomy among a population-based patient cohort whose treatment reflects contemporary surgical practice.

Design, Setting, and Patients We performed a retrospective cohort study of Medicare beneficiaries with clinical stage T1a kidney cancer treated with partial or radical nephrectomy from 1992 through 2007. Using an instrumental variable approach to account for measured and unmeasured differences between treatment groups, we fit a 2-stage residual inclusion model to estimate the treatment effect of partial nephrectomy on long-term survival.

Main Outcome Measures Overall and kidney cancer–specific survival.

Results Among 7138 Medicare beneficiaries with early-stage kidney cancer, we identified 1925 patients (27.0%) treated with partial nephrectomy and 5213 patients (73.0%) treated with radical nephrectomy. During a median follow-up of 62 months, 487 (25.3%) patients treated with partial nephrectomy and 222 patients (4.3%) treated with radical nephrectomy died of kidney cancer. Kidney cancer–specific survival was associated with improved survival.

Conclusion Among Medicare beneficiaries with early-stage kidney cancer who were candidates for either surgery, treatment with partial rather than radical nephrectomy was associated with improved survival.

JAMA. 2012;307(15):1629-1635

©2012 American Medical Association. All rights reserved.

Author Affiliations: Dow Division of Health Services Research, Department of Urology (Drs Tan and Miller and Mr Ye), Departments of Health Management and Policy (Dr Norton) and Economics (Dr Norton), Center for Healthcare Outcomes & Policy (Drs Norton and Miller), Division of Urologic Oncology, Department of Urology (Drs Hafez and Miller), University of Michigan, Ann Arbor; National Bureau of Economic Research, Cambridge, Massachusetts (Dr Norton); and Department of Urology, University of Washington, Seattle (Dr Gore).

Corresponding Author: David C. Miller, MD, MPH, Department of Urology, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd, Bldg 520, 3rd Floor, #3172, Ann Arbor, MI 48109-2800 (dcmiller@umich.edu).
naturally occurring variation within observed data to balance both measured and unmeasured variables among treatment groups. By applying this technique to a population-based patient cohort, we can clarify the comparative effectiveness of partial vs radical nephrectomy in the treatment of patients with early-stage kidney cancer.

**METHODS**

**Data Source**

After this study was deemed exempt by the Institutional Review Board at the University of Michigan, we used linked data from the SEER program and the Centers for Medicare & Medicaid Services (using only Medicare data) to identify patients diagnosed with incident kidney cancer from 1992 through 2007. SEER is a nationally representative, population-based registry that collects data regarding cancer incidence, treatment, and mortality. Successful linkage with hospital and physician claims is achieved for more than 90% of patients whose primary health insurance is provided by the Medicare program.

**Cohort Identification**

After limiting our sample to patients with Medicare fee-for-service coverage, we identified a preliminary cohort of 9111 patients diagnosed with localized, nonurothelial kidney tumors 4 cm in size or less (ie, clinical stage T1a kidney cancer). We then excluded patients lacking claims for kidney cancer surgery, and those with claims suggesting a solitary kidney, bilateral tumors, and/or multifocal disease. This process yielded a sample comprising 7398 patients with early-stage kidney cancer.

**Treatment Variable and Patient Covariates**

Next, we used a validated claims-based algorithm to identify patients treated with partial or radical nephrectomy by either an open or laparoscopic approach. This served as the treatment variable for our analyses.

For each patient, we used SEER data to ascertain demographic information including age, sex, race and ethnicity, marital status, income and education, and cancer severity (grade and histology). We also assigned each patient to a rural or urban locale using rural-urban commuting area codes. We measured preexisting comorbidity using a modification of the Charlson index based on inpatient and outpatient claims submitted during the 12 months prior to surgery. We also used established claims algorithms to identify postoperative complications that occurred during the index hospitalization or within 30 days of surgery (eMethods 1 available at http://www.jama.com).

**Outcome Measures**

Our primary outcome was overall survival. We ascertained the occurrence of death from any cause based on the date of death provided in the Medicare files. We defined survival time as the interval from the date of surgery until the date of death or until May 31, 2010, (the last month for which vital status data were available). Using cause of death codes available through SEER for patients who died on or before December 31, 2008, we measured kidney cancer–specific survival as a secondary outcome.

**Statistical Methods**

We used \( \chi^2 \) tests to evaluate associations between surgical treatment (partial vs radical nephrectomy) and patient-level covariates. Next, we calculated Kaplan-Meier estimates for all-cause and kidney–cancer specific mortality, stratified by treatment. We compared mortality between treatment groups using the log-rank test.

One important concern with studies based on observational data is the potential for residual confounding due to unmeasured patient characteristics (or other relevant variables). If present, such confounding can lead to incorrect inferences regarding the effectiveness of different treatments. One strategy to address this limitation is the use of an instrumental variable analysis that is designed to balance both measured and unmeasured variables between treatment groups.

To be considered valid, an instrumental variable must satisfy 2 conditions: 

1. The variable must be highly associated with the treatment of interest (in this case, receipt of partial nephrectomy); and
2. The variable cannot be associated with the outcome (in this case, survival) except through its effect on the treatment received. Once a suitable instrument is identified, it can be used to generate pseudorandomization, thereby allowing estimation of the treatment effect. However, in contrast to a randomized controlled trial that identifies the average treatment effect, an instrumental variable analysis estimates the treatment effect for the marginal patient—or the patient in whom the likelihood of undergoing the treatment is based on the instrumental variable.

Guided by the published literature, we selected the differential distance to a partial nephrectomy physician as our instrumental variable; we defined this as the distance from the patient’s residence to the nearest physician performing at least 1 partial nephrectomy in the year of treatment minus the distance from the patient’s residence to the nearest surgeon performing any kidney cancer surgery. We calculated distances using the linear distance function in SAS version 9.2, which measures the number of miles between the centers of 2 ZIP codes. We were able to calculate differential distance for 7138 patients (97% of our preliminary sample) (eMethods 2). For this group of patients, we created a 4-category instrumental variable by assigning patients with a differential distance of zero (ie, the closest kidney cancer surgeon was also a partial nephrectomy surgeon) to a single category, and partitioning the remaining patients into 3 equally sized terciles. To assess its validity as an instrument, we confirmed that differential distance was highly correlated with receipt of partial nephrectomy (F statistic >10), but not associated with survival in a standard multivariable proportional hazards model. We also examined covariate balance across the differential distance categories; we noted greater balance in patient-level covariates across the categories of our instrument compared with the pooled sample (eMethods 2). We used a 2-stage residual inclusion estimation framework for the instrumental variable analysis. The residual inclusion approach has been shown to generate more consistent (and less biased)
estimates for a variety of nonlinear models and has been applied specifically to nonparametric survival models using a Weibull distribution. In the first-stage model, we measured the association between partial nephrectomy and our instrument, adjusting for patient-level covariates including surgical approach (laparoscopic vs open). From this model, we determined the raw residual for each patient by calculating the difference between the model-predicted probability of receiving partial nephrectomy and the actual treatment received. The residuals were then included as an additional covariate in our second-stage survival model.

In the second-stage model, we specified a Weibull distribution and estimated the association between treatment and survival (both overall and kidney-cancer specific), adjusting for patient-level covariates, surgical approach, and postoperative complications. We then calculated model-derived estimates (i.e., predicted probabilities) of 2-, 5-, and 8-year survival for patients treated with partial or radical nephrectomy. Using the estimated differences in survival between treatment groups, we also calculated the number needed to treat (with partial rather than radical nephrectomy) to avoid 1 death following kidney cancer surgery.

We performed several additional analyses to more clearly identify patient subgroups (based on age and comorbidity status) that might derive particular benefit from partial nephrectomy. To assess the robustness of our findings, we also performed 3 sensitivity analyses. First, because a small proportion of patients who undergo treatment are found to have less common pathological diagnoses (e.g., oncocytoma, lymphoma, nephroblastoma), we repeated our analyses after limiting our sample to patients with histologically confirmed renal cell carcinoma. Second, because access to partial nephrectomy may differ across urban vs rural environments (a consideration that could influence our instrumental variable), we also fit separate models for these patient groups. Third, to better estimate the contemporary treatment effect, we fit separate models for patients treated from 1992-1999 and from 2000-2007.

All statistical testing was 2-sided and carried out at the 5% significance level. Analyses were performed using SAS version 9.2 and STATA version 11.0.

### RESULTS

Among 7138 patients treated surgically for clinical stage T1a kidney cancer, we identified 1925 (27.0%) and 5213 (73.0%) treated with partial or radical nephrectomy, respectively.
Patients treated with partial nephrectomy were younger, more often men, and resided in census tracts with higher levels of average income and education than those treated with radical nephrectomy (P value <.001; TABLE 1).

During a median follow-up of 62 months (interquartile range, 39-92 months), 487 (25.3%) and 2164 (41.5%) patients died from any cause after partial or radical nephrectomy, respectively. Kidney cancer was identified as the cause of death for 37 patients (1.9%) treated with partial nephrectomy and 222 patients (4.3%) treated with radical nephrectomy (eTable). Estimates of overall and kidney cancer-specific mortality are shown in FIGURE 1. In these unadjusted analyses, patients treated with partial nephrectomy had lower overall and kidney cancer-specific mortality (P value <.001).

The differential distance instrument was strongly associated with receipt of partial nephrectomy (x^2 test; P < .001); patients living closer to a partial nephrectomy physician were more likely to receive this treatment (FIGURE 2). This relationship persisted in a multivariable model that adjusted for all measured patient characteristics (F statistic = 97.3). Furthermore, in a standard proportional hazards survival model, we observed no independent association between the instrument and overall survival (hazard ratio [HR], 1.03; 95% CI, 0.99-1.07). Taken together, these findings suggest strongly that differential distance satisfies the 2 principal conditions for a valid instrument.

The 2-stage residual inclusion model estimates based on this instrument indicate that patients treated with partial nephrectomy had a significantly lower likelihood of death than those treated with radical nephrectomy (HR, 0.54; 95% CI, 0.34-0.85). We found no difference in kidney cancer–specific survival between treatment groups (HR, 0.82; 95% CI, 0.19-3.49). Model-predicted survival probabilities for patients treated with partial vs radical nephrectomy are presented in FIGURE 3. The predicted survival improvement for patients treated with partial nephrectomy was 5.6 (95% CI, 1.9-9.3), 11.8 (95% CI, 3.9-19.7), and 15.5 (95% CI, 5.0-26.0) percentage points at 2, 5, and 8 years following surgery, respectively. This corresponds with a number needed to treat of 18, 9, and 7 patients at 2, 5, and 8 years posttreatment, respectively. In other words, treating 7 patients with partial rather than radical nephrectomy would avoid 1 death during 8 years of follow-up.

In subgroup analyses, we observed that the survival benefit associated with partial nephrectomy may be greatest for patients younger than 75 years and for those with a Charlson comorbidity index score of 1 or higher. Our findings did not change substantively when we limited our sample to patients with renal cell carcinoma, those living in urban settings, and patients treated in more recent years (TABLE 2).
COMMENT

Current treatment guidelines for patients with early-stage kidney cancer are informed mainly by observational studies suggesting that partial nephrectomy yields oncologic outcomes that are equivalent to those for radical nephrectomy, while at the same time, reducing the risk of death from chronic kidney disease. It is presumed, but not established, that the downstream sequelae of chronic kidney disease lead to excess mortality and therefore less favorable survival outcomes among patients treated with radical nephrectomy. However, because the data supporting a survival advantage for partial nephrectomy are observational, the potential for selection bias and residual confounding limits causal inference regarding the relationship between treatment with partial nephrectomy and long-term survival. This concern is accentuated by recent data from a randomized trial demonstrating improved survival for patients treated with radical nephrectomy. Indeed, despite its many flaws, including accrual difficulties, protocol revisions, higher rates of crossover for the partial nephrectomy group, and premature closure, the EORTC study has generated widespread and early acceptance of partial nephrectomy as the preferred treatment option for the ever-expanding pool of patients with small, early-stage kidney cancers.

However, because the data supporting a survival advantage for partial nephrectomy are observational, the potential for selection bias and residual confounding limits causal inference regarding the relationship between treatment with partial nephrectomy and long-term survival. This concern is accentuated by recent data from a randomized trial demonstrating improved survival for patients treated with radical nephrectomy. Indeed, despite its many flaws, including accrual difficulties, protocol revisions, higher rates of crossover for the partial nephrectomy group, and premature closure, the EORTC study has generated new uncertainty regarding the comparative effectiveness of treatment with partial vs radical nephrectomy.

We sought to clarify this issue by performing an instrumental variable analysis based on a large population-based cohort of patients whose treatment more accurately reflects contemporary practice patterns and surgical techniques. With this approach, we did not replicate findings from the EORTC trial. Instead, we found that for patients with early-stage kidney cancer, treatment with partial nephrectomy was associated with better overall and equivalent cancer-specific survival. Based on a predicted survival difference of 15.5 percentage points at 8-year follow-up, 1 life would be saved for every 7 patients treated with partial rather than radical nephrectomy. Accordingly, our findings support partial nephrectomy as the preferred treatment option for the ever-expanding pool of patients with kidney tumors measuring 4 cm or smaller.

There are several possible reasons why our results contradict evidence from the randomized EORTC trial. It is plausible that in the absence of true randomization, the survival advantage with partial nephrectomy reflects residual unmeasured differences between treatment groups. The degree to which an instrumental variable analysis alleviates this concern depends on the selection of an instrument that induces meaningful variation in the treatment without independently influencing the outcome of interest. Consistent with previous work, differential distance categories met these criteria convincingly in our analysis. As such, our methods should have effectively balanced both measured and unmeasured variables between the treatment groups, mollifying concerns that the observed findings are due to bias or confounding.

Instead, the discordance with trial results likely reflects the influence of distinct treatment eras. At the outset of the EORTC study, there were widespread concerns regarding the oncologic effectiveness of partial nephrectomy. Outside of the trial setting, therefore, this procedure was reserved mainly for patients with a solitary kidney or chronic

**Table 2. Estimated Treatment Effect of Partial vs Radical Nephrectomy**

<table>
<thead>
<tr>
<th>Subgroup analyses</th>
<th>Partial Nephrectomy</th>
<th>Radical Nephrectomy</th>
<th>Overall Survival, HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients aged &lt;75 y</td>
<td>259/1203</td>
<td>962/2801</td>
<td>0.47 (0.24-0.92)</td>
</tr>
<tr>
<td>Patients aged ≥75 y</td>
<td>228/722</td>
<td>1202/2412</td>
<td>0.63 (0.34-1.17)</td>
</tr>
<tr>
<td>Charlson Index score = 0</td>
<td>215/1108</td>
<td>1042/3017</td>
<td>0.75 (0.38-1.45)</td>
</tr>
<tr>
<td>Charlson Index score ≥1</td>
<td>272/817</td>
<td>1122/2196</td>
<td>0.40 (0.21-0.75)</td>
</tr>
<tr>
<td>Sensitivity analyses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal cell carcinoma only</td>
<td>457/1829</td>
<td>2059/4987</td>
<td>0.53 (0.33-0.84)</td>
</tr>
<tr>
<td>Urban residence</td>
<td>412/1624</td>
<td>1801/4303</td>
<td>0.56 (0.33-0.92)</td>
</tr>
<tr>
<td>Rural residence</td>
<td>75/301</td>
<td>363/910</td>
<td>0.45 (0.16-1.30)</td>
</tr>
<tr>
<td>Treatment years 1992-1999</td>
<td>126/201</td>
<td>998/1288</td>
<td>0.58 (0.28-1.27)</td>
</tr>
<tr>
<td>Treatment years 2000-2007</td>
<td>361/1724</td>
<td>1226/3925</td>
<td>0.48 (0.27-0.86)</td>
</tr>
</tbody>
</table>

Abbreviation: HR, hazard ratio.

©2012 American Medical Association. All rights reserved.
renal insufficiency who were treated at a relatively limited number of centers.\textsuperscript{13,31,34} It was not until very late in the trial's accrual period that partial nephrectomy was utilized with any frequency as an elective procedure among patients with a normal contralateral kidney, suggesting that many treating surgeons and hospitals possessed limited experience with this complex surgical procedure.\textsuperscript{13,33,35} In the last decade, however, partial nephrectomy has been more widely adopted and the surgical technique has been modified in ways that reduce complication risks, ease convalescence, and better preserve function of the remnant kidney.\textsuperscript{30,35-38} Accordingly, both the patients receiving partial nephrectomy, and the procedure are likely quite different now than during the clinical trial. In this context, rather than viewing them as contradictory, we believe results from the EORTC study provide mainly historical context, while our findings reflect the current comparative effectiveness of partial vs radical nephrectomy.

Our study has several limitations. Because the sample includes only Medicare beneficiaries, our results may not be generalizable to younger patients with kidney cancer. The analysis is also limited to patients with the smallest kidney tumors ($\leq 4$ cm); as such, our findings may not pertain to patients with larger masses. In addition, our analyses did not account for potential treatments for recurrent or metastatic kidney cancer. However, because surgical cure rates exceed 90\% for patients with early-stage tumors, the number of patients who received these treatments is likely to be small and evenly distributed among patients treated with partial or radical nephrectomy.\textsuperscript{4,7,10,12,32,39} Additionally, it is plausible that our instrument (differential distance) may serve as a proxy for quality of care—namely that patients living closer to a partial nephrectomy physician may have access to better health care services, which ultimately influence their survival after kidney cancer surgery. That being said, the survival advantage with partial nephrectomy was maintained for patients residing in urban areas, where access to care is presumably less sporadic than in rural settings. Although our analysis identifies a survival advantage with partial nephrectomy, the mechanisms underlying this finding (eg, a reduction in postoperative chronic kidney disease and its attendant morbidity and excess mortality) require further clarification. The yet to be released renal functional outcomes from the EORTC trial may provide invaluable insights regarding the links between kidney cancer surgery, renal function, and nononcologic morbidity and mortality. Because we used an instrumental variable approach rather than actual randomization, our study identifies the treatment effect in the “marginal” rather than the average patient. Although characterizing this subpopulation can be difficult in the clinical setting,\textsuperscript{14,40} our subgroup analyses offer some insight into who may benefit most from partial nephrectomy.

These limitations notwithstanding, our findings have important implications for the care of patients with kidney cancer. By demonstrating that patients treated with partial nephrectomy live longer than those treated with radical nephrectomy, these data suggest that despite findings from the EORTC trial, partial nephrectomy is the best treatment for many patients with small, localized kidney cancers. Although use of partial nephrectomy has been increasing for the last decade,\textsuperscript{35,36} there are still many suitable patients who do not receive this operation, highlighting the need for continued efforts to accelerate its adoption.\textsuperscript{51} Because our subgroup analyses suggest that partial nephrectomy may be most beneficial for patients younger than 75 years of age and those with significant comorbidity, surgeons should pay particular attention to expanding the use of partial nephrectomy in patients meeting these clinical criteria.\textsuperscript{41,42}

At the same time, however, we acknowledge that partial nephrectomy remains a technically challenging operation with potentially significant complications (eg, hemorrhage, urinary fistula) that are seen less frequently with radical nephrectomy.\textsuperscript{53} This concern cannot be ignored when making treatment decisions. Indeed, the benefits of partial nephrectomy must always be weighed against the risk of acute surgical morbidity. In certain scenarios, some patients may be better served with an uncomplicated radical nephrectomy. Likewise, alternative treatment options, including active surveillance and ablative therapies, may be particularly prudent for patients in whom the benefits of surgical removal are less apparent.

Nevertheless, surgical management is undertaken in the vast majority of patients diagnosed with this increasingly common malignancy.\textsuperscript{2,3,6} Our findings suggest that by judiciously expanding the use of partial nephrectomy, clinicians can optimize survival outcomes among patients seeking treatment for early-stage kidney cancer.

Author Contributions: Dr Miller had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Tan, Norton, Ye, Hafez, Gore, Miller.

Acquisition of data: Tan, Ye, Hafez, Miller.

Analysis and interpretation of data: Tan, Norton, Ye, Hafez, Gore, Miller.

Drafting of the manuscript: Tan, Norton, Ye, Miller.

Critical revision of the manuscript for important intellectual content: Hafez, Gore.

Statistical Analysis: Tan, Norton, Ye.

Obtaining funding: Miller.

Administrative, technical or material support: Tan, Norton, Ye, Hafez, Gore, Miller.

Supervision: Norton, Hafez, Gore, Miller.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gore reports being a member of the paid advisory board for Blue Cross Blue Shield of America; and the receipt of grants or pending grants from the National Institutes of Health and the National Cancer Institute. Dr Miller reports provision of consultancy services for United HealthCare; receipt of salary from Blue Cross Blue Shield of Michigan; receipt of lecture or speakers bureau honorarium from the American Society of Clinical Oncology; receipt of travel/accommodations/meeting expenses from the Kidney Cancer Association; and serving on the medical advisory board for the Kidney Cancer Association. The other authors report no disclosures.

Funding/Support: This research was supported by funding from the Agency for Healthcare Research and Quality (K08 HS018346-D1A1); the Edwin B. Rees Research Fellowship in Urology and Urology-Related Fields from the New York Academy of Medicine; and the University of Michigan Comprehensive Cancer Center.

Role of the Sponsors: The sponsors had no input on the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Online-Only Material: The eMethods 1 and 2 and the eTable are available at http://www.jama.com.
REFERENCES


©2012 American Medical Association. All rights reserved.